Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused ...

Williams, who has performed the National Anthem at baseball stadiums as part of Boehringer Ingelheim’s Breathless campaign, ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

For the seventh consecutive year, the Top Employer Institute has recognized Boehringer Ingelheim as a Top Employer in the ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 ...

Boehringer Ingelheim, the Germany-based research-driven biopharmaceutical company, has signed a Memorandum of Understanding (MoU) with Kenya's Mission for Essential Drugs and Supplies (MEDS) to expand ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Boehringer Ingelheim Pharmaceuticals, Inc. announced today the appointment of Brian Hilberdink as President, U.S. Human Pharma. His arrival comes at a pivotal time for the company, as Boehringer grows ...

Vaxitek HVT+IBD+H5 integrates COBRA technology to address the ongoing viral evolution challenges of avian influenza, as well ...

CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate ...

With VAXXITEK® HVT+IBD+H5, Boehringer Ingelheim is expanding its proven VAXXITEK® range with a new vaccine that protects ...